Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ImmunoGen Inc

+ Add to Watchlist

IMGN:US

8.9500 USD 0.4300 5.05%

As of 20:10:00 ET on 03/31/2015.

Company Profile for ImmunoGen Inc (IMGN)

ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.

Contact Information

ImmunoGen Inc

830 Winter Street
Waltham, MA 02451-1477
United States
Phone: 1-781-895-0600
Fax: 1-781-895-0611

Key Executives for ImmunoGen Inc (IMGN)

Daniel M Junius "Dan"President/CEODavid B Johnston "Dave"Exec VP/CFO
Sandra E PooleSenior VP:Technical OperationsCharles Q Morris "Charlie"VP/Chief Development Officer
Ellie HarrisonVP/Chief Human Resources OfcrCraig BarrowsVP/Secretary/General Counsel
Peter J WilliamsVP:Business DevelopmentCarol HausnerExec Dir:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil